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Killer immunoglobulin-like receptors (KIRs) are related to the activation and inhibition of NK cells and may
play an important role in the innate response against infection with viruses such as hepatitis C virus (HCV).
We examined whether the different combinations of KIRs with their HLA class I ligands influenced the
response to combined treatment (pegylated alpha interferon and ribavirin) of patients infected by HCV. A total
of 186 consecutive patients diagnosed with chronic HCV infection were analyzed. Seventy-seven patients
exhibited HCV RNA levels at 6 months posttreatment and were called nonresponders (NR), while 109 cleared
viral RNA and were named sustained viral responders (SVR). Patients were typed for HLA-B, HLA-Cw, KIR
genes, and HCV genotype. In our study, the frequency of the KIR2DL2 allele was significantly increased in NR
(P < 0.001; odds ratio [OR]  1.95), as was the frequency of the KIR2DL2/KIR2DL2 genotype (P < 0.005;
OR  2.52). In contrast, the frequencies of the KIR2DL3 genotype (P < 0.001) and KIR2DL3/KIR2DL3
genotype (P < 0.05; OR  0.54) were significantly increased in the SVR. Different combinations of KIR2DL2
and KIR2DL3 alleles with their ligands were analyzed. The frequency of the KIR2DL2/KIR2DL2-HLA-C1C2
genotype was significantly increased in the NR (P < 0.01; OR  3.15). Additionally, we found a higher
frequency of the KIR2DL3/KIR2DL3-HLA-C1C1 genotype in the SVR group (P < 0.05; OR  0.33). These
results were not affected by the HCV genotype. In conclusion, patients who carried the KIR2DL2/KIR2DL2-
HLA-C1C2 genotype were less prone to respond to treatment. However, the KIR2DL3/KIR2DL3-HLA-C1C1
genotype clearly correlated with a satisfactory response to treatment, defined by the clearance of HCV RNA.
Hepatitis C virus (HCV) infection is a common chronic
disease affecting over 170 million people worldwide (48).
Around 80% of these individuals evolve to chronic infection,
and 10 to 20% of patients develop cirrhosis over a 20-year
period. A minority (2%) progresses to hepatocellular carci-
noma annually (18). Several host factors including age, body
mass index (BMI), gender, fibrosis, cirrhosis, or the absence of
cirrhosis and several viral factors including viral genotype and
viral load can influence the response to treatment (6, 32, 42).
Pegylated alpha interferon (Peg-IFN-) plus ribavirin (com-
bined therapy) constitute the most effective therapy for the
treatment of chronic HCV infection (13). Since this treatment
carries serious side effects, it is necessary to identify those
patients who can clear HCV infection in order to reduce the
period of this aggressive therapy.
Natural killer (NK) cells are lymphocytes that play an im-
portant role in the host defense against HCV infection (14).
NK cell activity is determined by the balance of different sig-
nals received and the equilibrium between inhibitory and ac-
tivating receptors (3). Some receptors are specific for human
leukocyte antigen (HLA) class I molecules (4). NK cells check
the surface of the surrounding cells, detect the presence of
their HLA class I molecules, and then discriminate between
healthy, infected, or transformed cells (10). When NK cells
contact target cells, the resulting interactions of their receptors
produce either activating or inhibitory signals. If the expression
of HLA class I molecules on the target cell is absent or re-
duced, the inhibitory signal is not generated (25).
Killer cell immunoglobulin-like receptors (KIRs) are mem-
bers of a group of regulatory molecules expressed on NK cells
and a subset of T cells (30). This family of polymorphic genes
is located on chromosome 19 (19q13.4), within the leukocyte
receptor complex. The leukocyte receptor complex also en-
codes a number of genetically and functionally related genes.
KIRs with long cytoplasmic tails are inhibitors, based on the
presence of immunoreceptor tyrosine-based inhibition motifs
in their cytoplasmic domains. KIRs with short tails interact
with adaptor molecules such as DAP-12 (DNAX activation
protein), which contain immunoreceptor tyrosine-based acti-
vation motifs and transmit activating signals (24). Several in-
hibitory KIRs have been well defined. KIR2DL1 binds the
subset of HLA-Cw molecules with lysine at position 80 of the
heavy chain (HLA-C2 group). KIR2DL2 and KIR2DL3 bind
the subset of HLA-Cw molecules with asparagine at position
80 (HLA-C1 group) (34).
Studies that have associated KIR genotypes with diseases
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have identified mainly viral infections and autoimmune dis-
eases (22, 45). The importance of NK cells in the resolution of
viral infections has prompted studies that correlate KIRs and
their ligands with outcomes (12). Some studies identified a
relationship between KIR genotypes and outcomes with sev-
eral infectious agents such as human immunodeficiency virus
(27, 29), cytomegalovirus (7), hepatitis B virus (28), and HCV
(21, 26).
Recently, a protective association of the inhibitory recep-
tor KIR2DL3 with HLA-CAsn80 (HLA-C1) and its effect on
the course of HCV infection were described (21). The prev-
alence of KIR2DL3 and its ligand HLA-C1 is increased in
individuals who eliminate HCV spontaneously, in contrast
to those who remain chronically infected. The protective
effect of KIR2DL3/HLA-CAsn80 was observed only among
individuals who carried both homozygous genes and had
received a low HCV exposure dose. Recently, we found that
the frequency of HLA-Bw4I80 ligand and the activating re-
ceptor KIR3DS1 was increased healthy in HCV carriers
compared to patients who had developed hepatocellular
carcinoma (26).
The aim of this study was to investigate the influence of KIR
genes and KIR-HLA combinations on the response to com-
bined therapy with Peg-IFN--2b and ribavirin in a group of
patients with HCV infection.
MATERIALS AND METHODS
Patients. A group of 186 consecutive, unrelated Caucasian patients diagnosed
with chronic HCV infection were enrolled in the study between January 2004 and
December 2005. They were diagnosed by the Gastroenterology Service of the
Hospital Universitario Central de Asturias in Oviedo, Spain, and by the Clínica
Universitaria de Navarra in Pamplona, Spain. All patients were positive for
anti-HCV antibodies and HCV RNA in serum.
The patients received the same standard treatment of Peg-IFN--2b (1.5 g/kg
of body weight/week) and ribavirin (65 kg, 800 mg/day; 65 to 85 kg, 1,000
mg/day; 85 kg, 1,200 mg/day). The duration of the treatment was 24 weeks for
HCV genotype 2 or 3 and 48 weeks for HCV genotype 1 or 4. All patients were
monitored for at least 6 months posttreatment in order to establish the response,
in accordance with previously reported virological criteria (11). Patients were
classified into two treatment outcomes. Patients who did not mount a sufficient
anti-HCV response (nonresponders [NR]) were defined by a consistent positive
viral load during treatment, at its end, or at 6 months posttreatment. Another
group of patients was classified as sustained virological responders (SVR). The
SVR were defined by consistent undetectable HCV RNA levels in serum during
6 months posttreatment.
The protocol was approved by the ethics committees of both hospitals, and all
patients gave written informed consent before enrollment.
Immunological tests. Genomic DNA was extracted from peripheral blood with
the Magtration-MagaZorb DNA Common Kit-200 N by using the Magtration
12GC system (Precision System Science Co., Ltd., Woerrstadt, Germany). The
HLA-B, HLA-Cw, and KIR genes were typed by using Lifecodes HLA-SSO and
KIR-SSO typing kits (Tepnel Lifecodes Corporation, Stamford, United King-
dom) based on Luminex xMAP technology (Luminex Corp., Austin, TX) ac-
cording to the manufacturer’s instructions. Ambiguities in KIR typing were
resolved by PCR-single specific primer (SSP) in accordance with a method
previously described (16, 19).
Microbiological tests. Serum samples were obtained at least every month
before, during, and after treatment. These samples were frozen at 80°C within
4 h of collection. The RNA viral levels in serum and HCV genotypes were
determined. The HCV genotype was identified by the Versant HCV Genotype
2.0 assay (Bayer HealthCare, Tarrytown, NY). HCV RNA was quantified during
the treatment and follow-up periods by real-time PCR (Cobas TaqMan 48;
Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s in-
structions.
Statistical analysis. We used the chi-square (2) test to examine whether there
were observable differences between qualitative factors and the Student t test for
quantitative factors in independent samples. The different factors that may con-
tribute to the nonresponse to the treatment were compared by using a backward
stepwise logistic regression analysis. The effect of the KIR-HLA genotypes on
the clearance of HCV RNA in serum during treatment was estimated by the
Kaplan-Meier method and compared using the log-rank test. In order to perform
this statistical analysis, we have defined the HCV RNA death event as the mean
between the last positive and the first negative HCV RNA results, under the
prerequisite that the patient remained negative through the end of the period of
treatment (31). Sera were collected at intervals of 4 weeks, and samples with
undetectable levels of HCV RNA during treatment from patients with a “break-
through effect” (39) were not considered for statistical analysis. Data were
censored when patients finished their treatment. A P value of 0.05 was con-
sidered to be significant. Statistical data were calculated by using the SPSS 15.0
program (SPSS Inc., Chicago, IL).
RESULTS
Patient characteristics. The clinical and demographic char-
acteristics of the 186 patients are shown in Table 1. Seventy-
seven patients (41.4%) were listed as NR to the treatment, and
109 patients (58.6%) comprised the SVR group because they
exhibited no detectable HCV RNA levels throughout the 6
months posttreatment. The distribution of viral genotypes in
our cohort showed that HCV genotype 1 was the most preva-
lent in our study population and was significantly more resis-
tant to this treatment regimen (P  0.001; odds ratio [OR] 
4.22; 95% confidence interval [CI]  2.07 to 8.78). In contrast,
HCV genotype 3 was significantly more susceptible to this
treatment regimen (P  0.001; OR  0.12; 95% CI  0.05 to
0.33). Moreover, the body mass index (BMI) was significantly
higher for the NR group than for the SVR group (P  0.05).
HLA and KIR distribution in the cohort study. The frequen-
cies of HLA-B and HLA-Cw alleles in our patients were not
significantly different between the treatment outcomes. We
then examined the frequencies of the different KIR genes (Fig.
1). No statistically significant differences were found for most
allele combinations except for the KIR2DL2 and KIR2DL3
genes. Considering both genes as alleles of the same locus (20,
47), the frequency of KIR2DL2 was significantly increased in
NR (P  0.001; OR  1.95; 95% CI  1.26 to 3.03), whereas
the frequency of KIR2DL3 was significantly increased in the
SVR group (P  0.001) (Table 2).
We also analyzed the distribution of the homozygous and
heterozygous genotypes of both alleles. When the KIR2DL2
allele was homozygous, we found significant differences be-
tween the treatment outcomes. The KIR2DL2/KIR2DL2 ge-
notype significantly correlated with NR (P 0.005; OR 2.52;
95% CI  1.31 to 4.86). In contrast, the frequency of the
KIR2DL3/KIR2DL3 genotype was significantly associated
with viral clearance (P  0.05; OR  0.54; 95% CI  0.28 to
0.99). No significant differences were found between treatment
outcomes when both alleles were heterozygous.
Next, we analyzed the different interactions of KIR2DL2
and KIR2DL3 alleles with their HLA-Cw group 1 (HLA-
C1) ligands. When KIR2DL2 was homozygous and its ligand
HLA-C1 was heterozygous (KIR2DL2/KIR2DL2-HLA-
C1C2), we observed a significant increase in the frequency
of a poor response to treatment (P  0.01; OR  3.15; 95%
CI  1.32 to 7.51). In contrast, the KIR2DL3/KIR2DL3-
HLA-C1C1 genotype was associated with at least a 6-month
clearance of HCV (P  0.05; OR  0.33; 95% CI  0.1 to
0.99). We analyzed the remaining combinations of heterozy-
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gous KIR2DL2 and KIR2DL3 alleles with their ligands, but
no significant differences were observed.
We then decided to analyze the progressive effect of
KIR2DL3/KIR2DL3-C1C1 on the response to treatment. Pa-
tients were sorted according to KIR2DL3 and HLA-C geno-
types. The first group contained patients who carried the
KIR2DL3/KIR2DL3-HLAC1C1 genotype; the second one
contained patients who carried the KIR2DL3/KIR2DL3-
TABLE 1. Clinical and HCV characteristics of infected patients included in the present study
Characteristica
Value for group
P valuebAll patients
(n  186)
SVR
(n  109)
NR
(n  77)
Mean age (yr)  SD 47.2  12.9 43.6  7.5 49.5  10.4
Gender distribution 	no. of patients (%)

Male 135 (72.6) 83 (76.1) 52 (67.5)
Female 51 (27.4) 26 (23.9) 25 (32.5)
Mean wt (kg)  SD 70.5  13 68.3  11 72.1  13
Mean BMI (kg/m2)  SD 23.2  3.6 22.7  3.4 24.1  4.1 0.05
Median viral load before treatment (106 IU/ml) (IR) 5.3 (4.67) 5.38 (4.67) 5.17 (3.9)
Mean analytical levels before treatment (IU/liter)  SD
AST 62.6  16.3 59.8  14.5 68.7  17.5
ALT 108.5  19.4 98.5  18.9 114.3  20.5
GT 76.5  24.3 64.7  23.6 84.8  26.7
Mean ferritin level (ng/ml)  SD 262.6  46.3 247.7  24.1 281.1  35.2
Mean platelet level (103 U/ml)  SD 221.5  57.6 212.7  46.3 229.1  60.4
Mean cholesterol level (mg/dl)  SD 183.6  39.2 173.4  32.8 180.3  22.5
No. of patients (%) with:
Cirrhosis 5 (2.7) 2 (1.8) 3 (3.9)
Source of HCV infection of:
Blood transfusion 61 (32.8) 33 (30.3) 28 (36.4)
Drug use 55 (29.6) 36 (33) 19 (24.7)
Unknown 70 (37.6) 40 (36.7) 30 (38.9)
HCV genotype
1 126 (67.7) 61 (55.9) 65 (84.4) 0.001
2 5 (2.8) 4 (3.7) 1 (1.3)
3 44 (23.6) 39 (35.8) 5 (6.5) 0.001
4 11 (5.9) 5 (4.6) 6 (7.8)
a IR, interquartile range; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GT, gamma-glutamyltranspeptidase.
b All P values were not significant except as indicated.
FIG. 1. KIR allele frequencies for patients with chronic HCV compared to treatment outcome (for KIR2DL2, the P value was 0.001, the OR
was 1.95, and the 95% CI was 1.26 to 3.03; for KIR2DL3, the P value was 0.001).
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HLA-C1C2, KIR2DL2/KIR2DL3-HLA-C1C1, or KIR2DL2/
KIR2DL3-HLA-C1C2 genotype; and the last group consisted
of the remaining patients who were homozygous for
KIR2DL2, were homozygous for HLA-C2, or carried the
KIR2DL2/KIR2DL2-HLA-C2C2 genotype. This analysis re-
vealed a linear trend between the number of KIR2DL3–
HLA-C1 interactions and the odds of an SVR (2 for trend of
4.736; P  0.05).
The distribution of the frequencies of KIR3DL1 and
KIR3DS1 alleles and the interaction with their ligands
(HLA-B Bw4 allotypes) was compared with outcome. No as-
sociations were found between these genes and the response to
the treatment (data not shown).
Influence of KIR2DL genotype in combination with other
risk factors in the nonresponse to treatment. As previously
mentioned, the response to treatment is particularly ineffective
for the most prevalent HCV genotype, genotype 1 (23), but
patients with HCV genotype 2 or 3 are expected to have a
higher probability of treatment success. Other factors that
could contribute to the achievement of positive outcome are
gender, age, BMI, extent of fibrosis, HCV RNA levels, and the
presence or absence of cirrhosis. Using a backward stepwise
logistic regression model, we initially analyzed the influence of
these host and viral variables with KIR and HLA-Cw genetic
factors on the nonresponse to treatment. The resulting com-
parative model is represented in Table 3. The KIR2DL2/
KIR2DL2-HLA-C1C2 genotype had a correlation with poor
outcome (P  0.01; OR  4.12; 95% CI  1.68 to 10.1).
Moreover, consistent with data from previous studies, HCV
genotype 1 (P  0.005; OR  3.32; 95% CI  1.49 to 7.42)
contributed clearly to the nonresponse of this treatment. Sig-
nificant interactions between the different variables analyzed
were not detected, including BMI, which was statistically sig-
nificant in the univariate analysis. In this multivariate analysis,
the KIR2DL3/KIR2DL3-HLA-C1C1 genotype was not signif-
icantly associated with nonresponse to treatment.
Effect of the KIR-HLA genotype on the clearance of HCV
RNA at the end of the treatment. We determined the HCV
RNA levels in sera of our patient cohort during the treat-
ment period. For the Kaplan-Meier analysis, patients were
divided into two groups: the first group was composed of
patients with HCV genotype 1 or 4 (n  137), and the
second group was composed of patients with HCV genotype
2 or 3 (n  49) (Fig. 2). In group 1, 70.6% of the patients
who carried the KIR2DL3/KIR2DL3-HLA-C1C1 genotype
had a complete response and cleared HCV RNA (P  0.062
by log-rank test), which showed a trend for a protective
effect of this KIR-HLA genotype. In contrast, most patients
who carried the KIR2DL2/KIR2DL2-HLA-C1C2 genotype
did not clear HCV RNA (P  0.01 by log-rank test) by the
TABLE 2. Comparison of frequencies of KIR2DL2 and KIR2DL3 and their respective ligands to viral responsesa
Genotype
No. of patients with genotype (%)
OR 95% CI P value
SVR NR
2n  218 2n  154
KIR2DL2 83 (38.1) 84 (54.5) 1.95 1.26–3.03 0.001
KIR2DL3 135 (61.9) 70 (45.5) 0.001
KIR alleles n  109 n  77
2DL2/2DL2 22 (20.2) 30 (39) 2.52 1.31–4.86 0.005
2DL2/2DL3 39 (35.8) 24 (31.2) NS
2DL3/2DL3 48 (44) 23 (29.8) 0.54 0.28–0.99 0.05
HLA-C alleles n  109 n  77
HLA-C1C1 42 (38.5) 27 (35) NS
HLA-C1C2 46 (42.2) 42 (54.6) NS
HLA-C2C2 21 (19.3) 8 (10.4) NS
KIR-HLA combinations n  109 n  77
2DL2/2DL2  HLA-C1C1 10 (9.2) 10 (13) NS
2DL2/2DL2  HLA-C1C2 9 (8.3) 17 (22.1) 3.15 1.32–7.51 0.01
2DL2/2DL2  HLA-C2C2 3 (2.7) 3 (3.9) NS
2DL2/2DL3  HLA-C1C1 13 (11.9) 12 (15.6) NS
2DL2/2DL3  HLA-C1C2 17 (15.6) 11 (14.2) NS
2DL2/2DL3  HLA-C2C2 9 (8.3) 1 (1.3) NS
2DL3/2DL3  HLA-C1C1 19 (17.4) 5 (6.5) 0.33 0.1–0.99 0.05
2DL3/2DL3  HLA-C1C2 20 (18.3) 14 (18.2) NS
2DL3/2DL3  HLA-C2C2 9 (8.3) 4 (5.2) NS
a Statistical significance was calculated by using the 2 test. For KIR2DL2, an OR of 1 indicates a poor response to treatment. NS, not significant.
TABLE 3. Final step of a backward logistic regression analysis of
risk factors associated with nonresponse to anti-HCV treatmenta
Variable OR 95% CI P value
KIR2DL2/KIR2DL2-HLA-C1C2
genotype
4.12 1.68–10.1 0.01
HCV genotype 1 3.32 1.49–7.42 0.005
a In the initial analysis, factors such as gender, age (50 years), BMI (27
kg/m2), aspartate aminotransferase levels (more than two times the normal
value), alanine amino transferase levels (more than two times the normal value),
gamma-glutamyltranspeptidase levels (more than two times the normal value),
HCV RNA levels (400,000 IU/ml), and cirrhosis or absence of cirrhosis were
also included. In this analysis, the KIR2DL3/KIR2DL3-HLA-C1C1 genotype
was not significant.
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end of the treatment. Group 2 patients infected with HCV
genotype 2 or 3 exhibited similar associations between ge-
notypes and outcomes. All patients who carried the
KIR2DL3/KIR2DL3-HLA-C1C1 genotype cleared HCV
RNA (P  0.05 by log-rank test) after 24 weeks of treat-
ment, whereas patients who carried the KIR2DL2/
KIR2DL2-HLA-C1C2 genotype did not (P  0.005 by log-
rank test). Patients with the KIR2DL3/KIR2DL3-HLA-
C1C1 genotype cleared HCV RNA at a higher frequency
than did patients who carried the KIR2DL2/KIR2DL2-
HLA-C1C2 genotype.
Moreover, at the end of the follow-up period, 65.4% of
patients who carried the KIR2DL2/KIR2DL2-HLA-C1C2 ge-
notype were poor responders, whereas 79.2% of all patients
who carried the KIR2DL3/KIR2DL3-HLA-C1C1 genotype
were able to clear HCV RNA in serum by the end of treat-
ment. In a previous analysis, we did not find statistical differ-
ences when patients were divided into groups of early viral
responders, SVR, and NR (data not shown).
In conclusion, the KIR-HLA genotype can influence the
clearance of HCV RNA at the end of treatment independently
of the HCV genotype.
DISCUSSION
Several studies have identified specific genetic factors that
play an important role in the persistence of HCV infection
(41). It was also observed previously that some HLA alleles
clearly influence the resolution of other viral infections (1).
Thus, HLA molecules have been the focus of numerous studies
for establishing possible associations with the persistence or
the elimination of HCV (9, 40). Some associations between
certain KIRs with their HLA ligands and the progression of
HCV infection were also described previously (26).
In the present study, we analyzed the influence of KIRs on
the response to combined treatment. While the number of
patients was relatively small, we considered the homogeneity
of the group important. In spite of these limitations, we ob-
served that KIR2DL3 was associated with a sustained viral
immune response, while KIR2DL2 was clearly correlated with
a nonresponse. Furthermore, we found that KIR2DL3/
KIR2DL3-HLA-C1C1 was associated with a sustained virolog-
ical response, whereas KIR2DL2/KIR2DL2-HLA-C1C2 had a
significantly increased frequency in the NR population.
Previous studies suggested a model in which KIR-HLA com-
binations inhibit NK cells with different intensities (44, 46).
According to this model, KIR2DL1-HLA-C2 has the strongest
capacity of inhibition, followed by KIR2DL2-HLA-C1 and,
finally, by KIR2DL3-HLA-C1. The weaker inhibition of
KIR2DL3 may result in a greater activation of NK cells and,
consequently, a more efficient resolution of viral infection. The
effects of additional NK-activating receptors, such as NKG2D,
may lead to a higher efficacy of control against HCV infection.
The two KIR2DL1 (present in 98% of the individuals) and
KIR2DL2 receptors may, however, induce a more intense in-
hibition of NK cells and therefore reduce the efficacy of re-
solving HCV infection. Moreover, the different KIR2DL–
HLA-C interactions may further transmit inhibitory signals
with different strengths (37).
In agreement with those studies, we suggest that the
KIR2DL3/KIR2DL3-HLA-C1C1 genotype combination influ-
ences the generation of a sustained virological response, since
the inhibitory signals produced by KIR2DL1 and KIR2DL2
are absent. Individuals who carry the KIR2DL3/KIR2DL3-
HLA-C1C1 genotype more effectively activated NK cells in
response to the administration of Peg-IFN- during treatment,
although NK cell functions have been impaired during chronic
HCV infection (15). Furthermore, several studies described
HCV mechanisms that inhibited the responses of NK cells and
were correlated with the establishment of a chronic infection
(17, 43). Nevertheless, recent findings demonstrate that a sus-
tained response to combined treatment for patients with
chronic HCV infection is closely associated with increased
numbers of NK cells in the liver (49). Other KIR2DL-HLA
genotypes have at least one stronger inhibitory signal, and their
response to treatment was less effective. Within these geno-
types, we suggest that the KIR2DL2/KIR2DL2-HLA-C1C2
genotype has the most inefficient response to treatment, be-
cause cumulative inhibitory signals are produced by KIR2DL1
and KIR2DL2. This stronger inhibition could be enhanced by
treatment because Peg-IFN- induces the expression of HLA
class I molecules (38) and favors the interaction between the
infected cells and NK cells.
We further observed that the homozygous KIR2DL3 allele
in combination with homozygous HLA-C1 was found signifi-
cantly more frequently in patients who responded to antiviral
treatment. The nonresponding patients had a higher frequency
of the homozygous KIR2DL2 allele with its heterozygous li-
gand, supporting our hypothesis. As previously mentioned,
Khakoo et al. (21) described that the presence of the homozy-
gous KIR2DL3 allele and its ligand is correlated to the spon-
taneous clearance of HCV infection. Our study shows a similar
association, but in this case, KIR2DL3/KIR2DL3-HLA-C1C1
is significantly associated with a complete response to antiviral
therapy, while the presence of the KIR2DL2/KIR2DL2-HLA-
C1C2 genotype correlates with an inadequate response to the
treatment and with persistent viral RNA. Despite the obser-
vation that the KIR2DL2/KIR2DL2-HLA-C2C2 genotype car-
ries the strongest inhibitory signal mediated by KIR2DL1-
FIG. 2. Percentage of complete response (CR) to combined treat-
ment before the follow-up period. Note that for patients with HCV
genotypes 2 and 3, there were 24 weeks of treatment. For patients with
HCV genotypes 1 and 4, there were 48 weeks of treatment.
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HLA-C2, we did not detect statistical differences related to a
nonresponse to treatment. Possible explanations include its
low frequency in our population and/or the absence of an
additional KIR2DL2-HLA-C1 inhibitory signal. Moreover, the
bound peptides in MHC class I play an important role in the
balanced recognition of NK cells, and the level of KIR2DL1
recognition of this complex may be reduced by some modified
peptides during tumor transformation or viral infections (2).
The monitoring of HCV RNA levels in serum throughout
the treatment period revealed a high percentage of patients
carrying KIR2DL3/KIR2DL3-HLA-C1C1 who exhibited a
complete response. In contrast, the majority of individuals
carrying the KIR2DL2/KIR2DL2-HLA-C1C2 genotype were
unable to clear HCV RNA. These data also suggested that
treatment in the presence of the KIR2DL2/KIR2DL2-HLA-
C1C2 genotype will be less effective in resolving HCV infec-
tion.
Analysis of the risk factors in the NR to the treatment
showed significant associations only with BMI, the HCV ge-
notype, the KIR genotype, and the KIR-HLA genotype. Pre-
vious studies have shown that HCV genotypes influence the
response to treatment (50). For example, HCV genotype 1 is
associated with a poor response to antiviral treatment (36),
similar to our results. Several studies suggested that HCV
genotype 1 is more resistant to treatment due to the interac-
tions of certain viral proteins, such as NS5A, with the IFN-
signaling pathway (35). In fact, five HCV-infected patients
carrying the KIR2DL3/KIR2DL3-HLA-C1C1 allele did not
resolve their infections after therapy in our study, which sug-
gests that additional modalities for resolving HCV infections
are warranted. On the other hand, antiviral treatment is usu-
ally efficacious against HCV genotypes 2 and 3 and justifies a
shorter treatment schedule (8).
CD8 T lymphocytes, as NK cells, are crucial in the defense
against viral infections. With regard to CD8 T lymphocytes
and HLA class I molecules, several studies indicated a central
association with the resolution of viral diseases (33). On the
other hand, CD8 T lymphocytes can express KIRs, and the
signals from these receptors can contribute to the control of
viral infections (5).
In conclusion, the balance of activating and inhibitory sig-
nals on NK cells and CD8 T lymphocytes, which is modulated
by treatment and conditioned by genetics, helps to define the
antiviral response. In addition to the viral genotype, KIRs play
an important role in the immune response against HCV and
may be key factors that modulate the progression of the infec-
tion and the response to treatment.
Despite the small number of subjects included in this study,
we were able to demonstrate significant effects of KIRs and
their ligands on the response to treatment of chronic HCV
infection. Nevertheless, additional genetic and functional stud-
ies will be necessary in order to clarify the involvement of KIRs
in HCV infection.
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